IMPAIRED PROLIFERATION AND DIFFERENTIATION OF MYELODYSPLASTIC CD34+ CELLS

被引：12
作者：
SAWADA, K
机构：
[1] Department of Internal Medicine II, Hokkaido University School of Medicine, Sapporo
来源：
LEUKEMIA & LYMPHOMA | 1994年 / 14卷 / 1-2期
关键词：
MDS; CD34; PURIFICATION; SERUM-FREE MEDIUM; G-CSF;
D O I：
10.3109/10428199409049649
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis resulting in refractory cytopenia(s), and increased risk of transformation into acute myeloblastic leukemia (AML). The widely used classification defined by the French-American-British group (FAB) recognizes 5 cytological subtypes of different prognosis, based essentially on the presence and the frequency of marrow blasts. The percentage of marrow blasts does not exceed 30%, hence, direct investigations of biological and biochemical events of MDS blast cells have been hampered. The CD34 antigen is currently unique in its narrow specificity of expression on human lymphohematopoietic progenitor cells. This cell membrane phosphoglycoprotein has been used for immunologic blast cell purification, notwithstanding the frequency of marrow blasts, and has provided a set of tools for investigations of MDS i.e. a direct comparison of the nature of blast cells in each of the MDS subtypes, using immunologic, biologic, biochemical and molecular biological methodology. A combination of serum-free medium and a purification method for blast cells provided evidence that the progenitor eel growth abnormalities in these disorders involve a defect in the capacity of progenitor cells to respond to stimulation with growth factor(s), and has presented direct evidence for the manner in which myelodysplastic CD34(+) cells are impaired.
引用
收藏
页码：37 / 47
页数：11
相关论文
共 116 条
  • [1] Saarni M.I., Linman J.W., Preleukemia: The hematologic syndrome preceding acute leukemia, Am. J. Med., 55, pp. 38-48, (1973)
  • [2] Greenberg P.L., Mara B., The preleukemic syndrome. Correlation of in vitro parameters of granulopoiesis with clinical features, Am. J. Med., 66, pp. 951-958, (1979)
  • [3] Koeffler H.P., Golde D.W., Human preleukemia, Ann. Intern. Med., 93, pp. 347-353, (1980)
  • [4] Linman J.W., Bagby G.C., The smoldering myeloid leukemic states. Clinical and biologic features, Blood, 61, pp. 1035-1044, (1983)
  • [5] Greenberg P.L., The smoldering myeloid leukemic states. Clinical and biologic features, Blood, 61, pp. 1035-1044, (1983)
  • [6] Prchal J.T., Throckmorton D.W., Carroll A.J., Fuson E.W., Gams R.A., Prchal J.S., A common progenitor for human myeloid and lymphoid cells, Nature, 274, pp. 590-591, (1978)
  • [7] Abkowitz J.L., Fialkow P.J., Niebruge D.J., Raskind W.H., Adamson J.W., Pancytopenia as a clonal disorder of a multipotent hemopoietic stem cell, J. Clin. Invest., 73, pp. 258-261, (1984)
  • [8] Raskind W.H., Tirumali N., Jacobsen R., Singer J., Fialkow P.J., Evidence for a multistep pathogenesis of a myelodysplastic syndrome, Blood, 63, pp. 1318-1323, (1984)
  • [9] Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C., Proposals for the classification of the myelodysplastic syndromes, Br. J. Haematol., 51, pp. 189-199, (1982)
  • [10] Nathan D.G., Chess L., Hillman D.G., Clarke B., Breard J., Merler E., Housman D.E., Human erythroid burst-forming unit: T-cell requirement for proliferation in vitro, J. Exp. Med., 147, pp. 324-339, (1978)
12345678910